Lemaitre Vascular INC

LeMaitre Vascular announced robust Q2 2026 financial results, exceeding expectations with 10% sales growth, improved gross margins, and a 23% increase in EPS, alongside positive future guidance.

LeMaitre Vascular announced robust Q1 2026 financial results, exceeding expectations with significant sales and EPS growth, and increased its full-year guidance.

LeMaitre Vascular announces director Bridget Ross will not seek re-election, with David B. Roberts nominated to fill a Class II director role and conditionally resign from Class I.

LeMaitre Vascular, Inc. announced robust Q4 2025 financial results, including 16% sales growth and 47% operating income growth, alongside a 25% increase in its quarterly dividend and a new $100 million share repurchase program.

LeMaitre Vascular's Board of Directors has decided to hold future Say-on-Pay votes on an annual basis, aligning with stockholder preference.

LeMaitre Vascular, Inc. announced robust Q3 2025 financial results, driven by double-digit sales growth and increased profitability, leading to an upward revision of its full-year guidance.

LeMaitre Vascular, Inc. announced a 10% increase in net sales for Q2 2026, driven by strong performance in grafts, shunts, and patches, alongside improved gross margins.

LeMaitre Vascular, Inc. announced a 11% increase in net sales for Q1 2026, driven by strong performance in grafts, valvulotomes, and shunts, alongside improved gross margins.

LeMaitre Vascular, Inc. announced robust financial results for the third quarter and first nine months of 2025, driven by increased sales across all geographies and improved gross margins.

LeMaitre Vascular, Inc. announced robust financial results for Q2 2025, with net sales increasing 15% and net income rising 16.5% year-over-year, alongside significant corporate governance updates.

LeMaitre Vascular announces a 12% increase in net sales for the first quarter of 2025, driven by higher average selling prices and unit volumes.

LeMaitre Vascular's Q3 2024 results show significant growth in net sales and gross profit, driven by strong performance across all geographic regions and key product lines.

LeMaitre Vascular, Inc. announced robust financial results for 2025, driven by increased sales, improved margins, and strategic expansions, alongside an increased quarterly dividend.

LeMaitre Vascular's 2024 10-K filing reveals a year of growth driven by strategic acquisitions, sales force expansion, and increased pricing, alongside ongoing efforts to navigate regulatory landscapes and optimize manufacturing.

LeMaitre Vascular's 2023 annual report highlights a 20% increase in net sales and a 37% rise in operating income, fueled by higher prices, increased procedure volumes, and strategic acquisitions.

Director Lawrence J. Jasinski reported the acquisition of dividend equivalent rights on existing equity awards.

Director John James O'Connor reported the accrual of dividend equivalent rights related to existing equity awards.

Director John A. Roush reported the accrual of dividend equivalent rights on existing equity awards.

Director Martha Shadan of LeMaitre Vascular, Inc. reported the acquisition of dividend equivalent rights related to existing equity awards.

Director Joseph P. Pellegrino Jr. acquired additional dividend equivalent rights related to existing equity awards.

CFO Dorian Paul LeBlanc acquired additional dividend equivalent rights related to existing restricted stock unit awards.

LeMaitre Vascular, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, detailing proposals for director elections, executive compensation approval, and auditor ratification.

LeMaitre Vascular is urging stockholders to vote in favor of its three director nominees, including the CEO, President, and an independent director, despite a recommendation from Institutional Shareholder Services (ISS) to withhold votes.

LeMaitre Vascular, Inc. has filed a definitive proxy statement with the SEC.

LeMaitre Vascular will hold its 2025 Annual Meeting of Stockholders on June 2, 2025, to vote on director elections, executive compensation, and auditor ratification.

LeMaitre Vascular is soliciting proxies for its 2024 Annual Meeting of Stockholders, focusing on director elections, executive compensation, and approval of an amended stock option plan.

First Trust Portfolios L.P., First Trust Advisors L.P., and The Charger Corporation have jointly filed a Schedule 13G, reporting beneficial ownership of 5.15% of LeMaitre Vascular, Inc. common stock.

George W. LeMaitre has filed a Schedule 13G, reporting beneficial ownership of 1,465,235 shares of LeMaitre Vascular, Inc. common stock, representing 6.4% of the outstanding shares.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in LeMaitre Vascular Inc. following an internal corporate realignment.

Conestoga Capital Advisors has reported a beneficial ownership of 6.73% in Lemaitre Vascular Inc., holding over 1.5 million shares as of December 31, 2025.

George W. LeMaitre, Chairman and CEO of LeMaitre Vascular, Inc., reported beneficial ownership of 7.43% of the company's common stock as of September 30, 2025.

BlackRock, Inc. has filed an Amendment No. 4 to Schedule 13G, reporting a beneficial ownership of 13.8% of Lemaitre Vascular Inc.'s common stock as of March 31, 2025.